We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.


Previous 10 Next 10 
To: Madharry who wrote (27)10/9/2001 9:31:24 PM
From: Biomaven
   of 146

Review of the S1 indicated that at that time there were almost 10 million options and warrants outstanding at prices around $1 or less so this should be factored in when considering purchase.

This is misleading. The vast majority of these were preferred shares that converted at the time of the IPO. As of the last 10-K, there were 1.5 million warrants with an exercise price of $3.50 and about the same number (maybe less) of in-the-money options (at today's price) outstanding.


P.S. I bought DDDP for the first time today. Some kind soul (Rick may likely offer a different epithet <g>) offering to sell me shares at under $5.50 looked like too good a deal for me to pass up.

Share RecommendKeepReplyMark as Last ReadRead Replies (2)

To: Biomaven who wrote (36)10/9/2001 10:41:08 PM
From: scaram(o)uche
   of 146
Some kind soul (Rick may likely offer a different epithet <g>)

You mean like.......

"Some blasted soul that is going to rot in hell?"

Or sumthin?

Madharry..... correct or not, we appreciate the effort and te attempt to point at potential downside. Thanks! Thanks, Peter, for doing the digging and correcting.

If we all make calls, we all profit. Regardless of whether or not the calls are correct.

Share RecommendKeepReplyMark as Last ReadRead Replies (2)

To: Biomaven who wrote (36)10/10/2001 12:33:46 AM
From: Madharry
   of 146
Peter I went back and checked the S1 there were actually 10.6MM potential warrants and options excluded and then another 239,000 shares that were going to be converted at the time of the offering.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)

To: scaram(o)uche who wrote (37)10/10/2001 1:00:38 AM
From: Madharry
   of 146
I reserve the right to be wrong and frequently am. What bothers me just a little here is that Cavanaugh looks like he has bought lots of shares in the open market like 150,000. at the same time he runs health care ventures which owns over 12 million shares of DDDP and he got something like options to purchase 50000 shares of stock as a director.

Share RecommendKeepReplyMark as Last Read

To: Madharry who wrote (38)10/10/2001 9:12:46 AM
From: Biomaven
   of 146

Their latest 10-K discloses the following:

Securities and the related number of common shares not included in the diluted computation for the year ended December 31, 2000 that could potentially dilute basic earnings per share, if any, in the future are as follows:

Dilutive Potential
Common Shares *
<S> <C>
Preferred stock (see below)............................... 6,858,000
Options................................................... 2,115,000
Warrants.................................................. 1,531,000
Common stock--subject to repurchase....................... 179,000

* Includes weighted average shares for period prior to conversion and exercise.

The preferred stock automatically converted into common stock on a 1 for .36 basis and certain nonvested common stock automatically became vested upon completion of the initial public offering of the Company's common stock in August 2000.

So that 10.6MM number includes the preferred, which is now gone. I haven't looked at their S-1, which might have presented this differently.


Share RecommendKeepReplyMark as Last ReadRead Replies (1)

To: Biomaven who wrote (40)10/15/2001 8:34:31 PM
From: Madharry
   of 146
Sheesh. I posted a response to this the same day and I guess it did not take for some reason- I went back and looked at the last s1a before the company came public and it presented number much like your last post. I do not know what happened between the first s1 and the last one but your info was clearly more accurate. In the future i will review the first s1 and all the ammendments before opening my big mouth. Any way looks like you bought right once again - congratulations.

Share RecommendKeepReplyMark as Last Read

To: scaram(o)uche who wrote (37)10/29/2001 9:02:23 AM
From: scaram(o)uche
   of 146
Monday October 29, 8:32 am Eastern Time

Press Release

SOURCE: 3-Dimensional Pharmaceuticals, Inc.

Athersys and 3-Dimensional Pharmaceuticals Form
Drug Discovery and Development Collaboration

CLEVELAND, and YARDLEY, Pa., Oct. 29 /PRNewswire/ -- Athersys, Inc. and
3-Dimensional Pharmaceuticals, Inc. (Nasdaq: DDDP - news) today announced a
collaboration to discover, develop and commercialize novel, small molecule pharmaceuticals
by screening against therapeutically relevant drug targets derived from the G-Protein Coupled
Receptor (GPCR) family of proteins. This collaboration combines Athersys' functional
genomics expertise with 3-Dimensional Pharmaceutical's (3DP) small molecule drug
development capabilities for rapid drug identification and optimization of drug candidates.

Under the terms of the agreement, the companies will jointly select a number of biologically
validated targets having commercial or therapeutic value to be included in the collaboration.
Certain small molecule drug candidates identified from the collaboration will be jointly
developed, with the companies sharing future development costs and commercialization
rights, while others will be retained exclusively by each of the parties for future development
and commercialization.

Athersys will employ its proprietary RAGE (Random Activation of Gene Expression(TM))
technology platform to provide the collaboration access to cell lines that express the selected
drug targets. Athersys will use the cell lines to develop screens for drug discovery and screen
compounds using 3DP's DiscoverWorks® platform. 3DP will employ its DiscoverWorks®
platform to identify and optimize lead compounds active against the validated targets. 3DP's
technologies can be applied to virtually any disease target, and are used to produce small
molecule compounds suitable for drug development in a more timely and cost-effective
manner and with a higher probability of success than conventional methods.

``This collaboration combines two powerful drug discovery and development technologies,
making it possible for Athersys and 3DP to rapidly discover and develop small molecule
compounds against the biologically validated GPCR targets that Athersys and 3DP select for
development,'' commented Gil Van Bokkelen, Ph.D., Chairman, President and Chief
Executive Officer of Athersys. ``This marks another important milestone for Athersys as we
continue to expand our drug development capabilities by establishing strategic partnerships
with companies that have developed highly complementary technology platforms.''

``We see this collaboration as a highly synergistic combination of strong biology and chemistry capabilities that will quickly
achieve positive results,'' said David C. U'Prichard, Ph.D., Chief Executive Officer of 3DP. ``Access to proprietary, validated
targets for drug discovery and development is a key objective of 3DP and we are very pleased to enter into this collaboration
with Athersys.''

3DP ( is an integrated bio-pharmaceuticals company dedicated to revolutionizing small molecule drug
discovery and development. 3DP's proprietary platform, DiscoverWorks®, can be applied to virtually any potential drug
target. It produces drug candidates suitable for faster development, with fewer resources and a higher probability of success
than using conventional drug discovery methods. 3DP is developing its own drug pipeline and collaborates with other
pharmaceutical companies in discovery and development.

Athersys is a functional genomics and biopharmaceutical company engaged in the development, application and
commercialization of novel gene expression tools and therapeutic products. The company's research and development
programs are focused on its two proprietary platform technologies: RAGE (Random Activation of Gene Expression(TM)) and
SMC(TM) (Synthetic Microchromosome(TM)) vector system. RAGE is a novel gene expression system that provides the
unique ability to produce protein from virtually every gene in the human genome, without requiring the cloning of individual
genes or use of cDNA libraries. RAGE greatly accelerates the identification and validation of novel drug targets by enabling the
direct correlation of a disease process or characteristic with expression of a specific protein. As a result, RAGE has powerful
applications in functional genomics; the generation of validated drug targets; discovery of novel antibody drug targets; structural
proteomics and rational drug design; and the production of protein therapeutics. Athersys is developing novel therapeutic
products based on its proprietary technologies, through partnerships and internal research and development programs. This
press release and further information on Athersys, Inc. can be found on the World Wide Web at:

For Athersys: Statements herein that are not descriptions of historical facts are forward-looking and subject to risk and
uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors, including risks
relating to the early stage of products under development; uncertainties related to patent protection; uncertainties relating to
clinical trials; dependence on third parties, including strategic partners, collaborators and key personnel; and risks relating to the
development and commercialization, if any, of Athersys' proposed products (such as effectiveness of our products, marketing,
manufacturing, safety, regulatory, patent or product liability, supply, competition and other risks).

For 3DP: Statements in this press release that are not strictly historical are ``forward-looking'' statements which involve a high
degree of risk and uncertainty. Such statements are only predictions, and the actual events of results may differ materially from
those projected in such forward-looking statements. Factors that could cause or contribute to differences include, but are not
limited to, risks associated with our new and uncertain technologies, clinical trials and product development, the long and
arduous process of obtaining regulatory approval, our dependence on existing strategic alliances and new collaborations, our
dependence on patents and proprietary rights, our ability to protect and enforce our patents and proprietary rights, the
development and availability of competitive products or technologies, our ability to attract and retain talented employees and
our ability to manage our expansion as a company increasingly focused on internal product research and development.

SOURCE: 3-Dimensional Pharmaceuticals, Inc.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)

To: scaram(o)uche who wrote (42)10/29/2001 8:29:26 PM
From: Miljenko Zuanic
   of 146
<<Certain small molecule drug candidates identified from the collaboration will be jointly developed, with the companies sharing future development costs and commercialization rights, while others will be retained exclusively by each of the parties for future development and commercialization.>>

Will be nice to know is *exclusively* equally distributed? I will say not, but need to check with DDDP.


Share RecommendKeepReplyMark as Last ReadRead Replies (1)

To: Miljenko Zuanic who wrote (43)12/10/2001 6:19:02 PM
From: Miljenko Zuanic
   of 146
Monday December 10, 10:30 am Eastern Time
Press Release
SOURCE: AstraZeneca
AstraZeneca's Investigational Oral Anticoagulant Studied as Alternative to Warfarin for Stroke Prevention
Results Presented at American Society of Hematology
WILMINGTON, Del., Dec. 10 /PRNewswire/ -- Interim results of a Phase II trial comparing AstraZeneca's investigational oral direct thrombin inhibitor EXANTA (ximelagatran) to warfarin for the prevention of strokes in patients with chronic nonvalvular atrial fibrillation (NVAF) showed 0.9 strokes and 0.4 transient ischemic attacks (TIAs) per 100 treatment years (3 events) for patients on EXANTA and 2.6 strokes and 2.6 TIAs per 100 treatment years (4 events) for patients on warfarin.

Results of the SPORTIF IV trial were presented today at the 43rd annual meeting of the American Society of Hematology in Orlando, Florida. Both strokes observed in the patients treated with EXANTA were ischemic and non-fatal. Both strokes observed in the warfarin-treated patients were hemorrhagic and fatal.

SPORTIF IV is a long-term, open-label continuation of SPORTIF II, a 12-week randomized dose-finding study. In SPORTIF IV, 125 patients with chronic NVAF and at least one additional stroke risk factor received fixed-dose EXANTA (36 mg bid) and 42 patients received warfarin (dose-adjusted to an INR of 2-3). Patients have been treated for between 21 and 24 months; the study is ongoing. These preliminary results need to be confirmed in larger-scale clinical trials.

The incidence of major bleeding was 0.9 per 100 treatment years with EXANTA and 2.6 per 100 treatment years with warfarin. In the combined SPORTIF II/IV clinical trials, liver enzyme levels of at least three times the upper limit of normal were observed in approximately 5 percent of patients treated with EXANTA. None of these patients was symptomatic, and enzyme levels decreased during continued treatment or discontinuation of therapy.

EXANTA is the first oral direct thrombin inhibitor under Phase III investigation. The mechanism of action of EXANTA is to inhibit the activity of a clot-forming enzyme called thrombin, which is critical to the final step in the formation of blood clots. Ongoing clinical studies utilize a fixed dose of EXANTA without routine coagulation monitoring.

According to the American Heart Association, atrial fibrillation is found in about two million Americans. During atrial fibrillation, the two small upper chambers of the heart, called the atria, quiver instead of beating effectively. Blood in these quivering chambers can pool and clot. If a piece of the blood clot travels to an artery in the brain and becomes lodged, a stroke may result. About 15 percent of strokes in the United States occur in people with atrial fibrillation.

AstraZeneca (NYSE: AZN - news) is a major international healthcare business engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and the supply of healthcare services. It is one of the top five pharmaceutical companies in the world with healthcare sales of $15.8 billion and leading positions in sales of cardiovascular, gastrointestinal, oncology, anesthesia (including pain management), central nervous system (CNS) and respiratory products. In the United States, AstraZeneca is an $8 billion healthcare business with more than 10,000 employees.

For more information about AstraZeneca please visit

This press release contains forward-looking statements with respect to AstraZeneca's business. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the company's Annual Report/Form 20-F for 2000.

SOURCE: AstraZeneca

Share RecommendKeepReplyMark as Last ReadRead Replies (1)

To: Miljenko Zuanic who wrote (44)12/28/2001 12:35:10 AM
From: Miljenko Zuanic
   of 146
Why the F J&J can do anything on time and with satisfaction????

United States Patent 6,326,492

<<Thrombin: Thrombin activity was assessed as the ability to hydrolyze the substrate N-succinyl-Ala-Ala-Pro-Arg-p-nitroanilide. Substrate solutions were prepared at a concentration of 32 mM (32 mM<<Km=180 mM) in assay buffer. Final DMSO concentration was 4.3%. Purified human a-thrombin was diluted into assay buffer to a concentration of 15 nM. Final reagent concentrations were: [thrombin]=0.5 nM, [substrate N-succinyl-Ala-Ala-Pro-Arg-p-nitroanilide]=32 mM.

The compound of Example 1 had a thrombin inhibitory activity of 26 nM. The compound of Example 2 had a thrombin inhibitory activity of 0.38 nM. The results indicate that the compounds of the present invention are potent and highly selective inhibitors of thrombin.>>

Share RecommendKeepReplyMark as Last ReadRead Replies (1)
Previous 10 Next 10